The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways

References

• Kacetl J, Maresova P, Maskuriy R, et al. Ethical questions linked to rare diseases and orphan drugs - A systematic review. Risk Manag Healthc Policy. 2020 Oct;13(13):2125–2148. .
   PubMedGoogle Scholar
• Czech M, Baran–Kooiker A, Atikeler K, et al. A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries. Front Public Health. 2020 Jan 28;7:416. .
   PubMed Web of Science ®Google Scholar
• Mayrides M, Ruiz De Castilla EM, Szelepski S. A civil society view of rare disease public policy in six Latin American countries. Orphanet J Rare Dis. 2020 Feb 27;15(1):60,020-1314–z.
   PubMed Web of Science ®Google Scholar
• Zamora B, Maignen F, O’Neill P, et al. Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis. 2019 May 3;1(1):95,019–5.
   Google Scholar
• Giannuzzi V, Conte R, Landi A, et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis. 2017 Apr 3;12(1):64,017-0617-1.
   PubMedGoogle Scholar
• Malinowski KP, Kawalec P, Trabka W, et al. Reimbursement legislations and decision making for orphan drugs in central and Eastern European countries. Front Pharmacol. 2019 May 10;10:487. .
   PubMed Web of Science ®Google Scholar
• Volmar CH, Wahlestedt C, Brothers SP. Orphan diseases: state of the drug discovery art. Wien Med Wochenschr. 2017 Jun;167(9–10):197–204.
   PubMed Web of Science ®Google Scholar
• Sun W, Zheng W, Simeonov A. Drug discovery and development for rare genetic disorders. Am J Med Genet A. 2017 Sep;173(9):2307–2322.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monguio R, Spargo T, Seoane–Vazquez E. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? Orphanet J Rare Dis. 2017Jan5;12(1):1,016-0551-7.
   PubMedGoogle Scholar
• Godman B, Bucsics A, Vella Bonanno P, et al. Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Front Public Health. 2018 Dec;5(6):328.
   Google Scholar
• Pinxten W, Denier Y, Dooms M, et al. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European orphan drug regulation. J Med Ethics. 2012 Mar;38(3):148–153. .
   PubMed Web of Science ®Google Scholar
• Kinney J. Health disparities: exploring the ethics of orphan drugs. Am J Health Syst Pharm. 2014 May 1;71(9):692–693.
   PubMed Web of Science ®Google Scholar
• Cremers S, Aronson JK. Drugs for rare disorders. Br J Clin Pharmacol. 2017;83(8):1607–1613.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Poletti-Hughes J, Koomen JM. Profitability and market value of orphan drug companies: a retrospective, propensity-matched case-control study. PLoS One. 2016 Oct 21;11(10):e0164681.
   PubMed Web of Science ®Google Scholar
• Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today. 2012 Jul;17(13–14):660–664.
   PubMed Web of Science ®Google Scholar
• Mingorance A. Drivers of orphan drug development. ACS Med Chem Lett. 2018 Oct 1;9(10):962–964.
   PubMed Web of Science ®Google Scholar
• Davies EH, Fulton E, Brook D, et al. Affordable orphan drugs: a role for not-for-profit organizations. Br J Clin Pharmacol. 2017 Jul;83(7):1595–1601. .
   PubMed Web of Science ®Google Scholar
• Sakate R, Fukagawa A, Takagaki Y, et al. Trends of clinical trials for drug development in rare diseases. Curr Clin Pharmacol. 2018;13(3):199–208. .
   PubMed Web of Science ®Google Scholar
• Schuller Y, Biegstraaten M, Hollak CEM, et al. Oncologic orphan drugs approved in the EU - do clinical trial data correspond with real–world effectiveness? Orphanet J Rare Dis. 2018 Nov 28;13(1):214,018-0900-9.
   PubMedGoogle Scholar
• Putzeist M, Mantel-Teeuwisse AK, Llinares J, et al. EU marketing authorization review of orphan and non-orphan drugs does not differ. Drug Discov Today. 2013 Oct;18(19–20):1001–1006. .
   PubMed Web of Science ®Google Scholar
• Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012 Apr 1;30(10):1030–1033.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011 Jun 8;305(22):2320–2326.
   PubMed Web of Science ®Google Scholar
• Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014 Nov;9(1):170. . 014-0170-0.
   PubMedGoogle Scholar
• Fonseca DA, Amaral I, Pinto AC, et al. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today. 2019 Mar;24(3):867–872. .
   PubMed Web of Science ®Google Scholar
• Jayasundara K, Hollis A, Krahn M, et al. Estimating the clinical cost of drug development for orphan versus non–orphan drugs. Orphanet J Rare Dis. 2019 Jan 10;305(22):12,018–4.
   Google Scholar
• Kawalec P, Sagan A, Pilc A. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Orphanet J Rare Dis. 2016 Sep 6;11(1):122,016-0501-4.
   PubMedGoogle Scholar
• Mardiguian S, Stefanidou M, Sheppard F. Trends and key decision drivers for rejecting an orphan drug submission across five different HTA agencies. Value Health. 2014 Nov;17(7):A438.
   PubMed Web of Science ®Google Scholar
• Miller KL, Lanthier M. Investigating the landscape of US orphan product approvals. Orphanet J Rare Dis. 2018 Oct 22;13(1):183. 018-0930-3.
   PubMedGoogle Scholar
• Wellman-Labadie O, The ZY. US orphan drug act: rare disease research stimulator or commercial opportunity? Health Policy. 2010 May;95(2–3):216–228.
   PubMed Web of Science ®Google Scholar
• Blankart CR, Stargardt T, Schreyogg J. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, fabry disease, hereditary angioedema and chronic myeloid leukaemia. Pharmacoeconomics. 2011 Jan;29(1):63–82.
   PubMed Web of Science ®Google Scholar
• Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):23–29.
   PubMed Web of Science ®Google Scholar
• Denis A, Mergaert L, Fostier C, et al. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy. 2010;8(5):343–350. .
   PubMedGoogle Scholar
• Trama A, Pierannunzio D, Loizzo A, et al. Availability of medicines for rare diseases in EU countries. Pharmaceuticals Policy and Law. 2009;11(1,2):101–109.
   Google Scholar
• Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, et al. Incentives for orphan drug research and development in the united states. Orphanet J Rare Dis. 2008 Dec;16(3):33,1172-3-33.
   Google Scholar
• Song P, Tang W, Kokudo N. Rare diseases and orphan drugs in Japan: developing multiple strategies of regulation and research. Expert Opin Orphan Drugs. 2013;1(9):681–683.
   Web of Science ®Google Scholar
• Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36–42. Winter. .
   PubMed Web of Science ®Google Scholar
• Picavet E, Dooms M, Cassiman D, et al. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011 Jul 1;9(4):275–279.
   PubMedGoogle Scholar
• Phillips M. Big pharma’s new model in orphan drugs and rare diseases. Exp Opin Orphan Drugs. 2013;1(1):1–3.
   Web of Science ®Google Scholar
• Kesselheim AS, Myers JA, Solomon DH, et al. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012;7(2):e31894. .
   PubMed Web of Science ®Google Scholar
• Picavet E, Morel T, Cassiman D, et al. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014 Apr;9(1):62. 1172-9-62.
   PubMedGoogle Scholar
• Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2009 Jan;14(1):63–71.
   Google Scholar
• Do N, Oh J, Lee JS. Moving toward universal coverage of health insurance in Vietnam: barriers, facilitating factors, and lessons from Korea. J Korean Med Sci. 2014 Jul;29(7):919–925.
   PubMed Web of Science ®Google Scholar
• Yoo SL, Kim DJ, Lee SM, et al. Improving patient access to new drugs in South Korea: evaluation of the national drug formulary system. Int J Environ Res Public Health. 2019 Jan 21;16(2):2. .
   Web of Science ®Google Scholar
• Kim S, Lee JH. Price-cutting trends in new drugs after listing in South Korea: the effect of the reimbursement review pathway on price reduction. Healthcare (Basel). 2020 Jul 26;8: 3. .
   Google Scholar
• Kim S, Cho H, Kim J, et al. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways. Expert Rev Pharmacoecon Outcomes Res. 2020;26:1–7.
   Google Scholar
• Kim S, Kim J, Cho H, et al. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years. Expert Rev Pharmacoecon Outcomes Res. 2020;17:1–10.
   Google Scholar
• Carapinha JL. Comment on the implications of external price referencing of pharmaceuticals in middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2016;14(1):11–14.
   Google Scholar
• Holtorf AP, Gialama F, Wijaya KE, et al. External reference pricing for pharmaceuticals- A survey and literature review to describe best practices for countries with expanding healthcare coverage. Value Health Reg Issues. 2019 Sep;19:122–131.
   PubMedGoogle Scholar
• Garcia Marinoso B, Jelovac I, Olivella P. External referencing and pharmaceutical price negotiation. Health Econ. 2011 Jun;29(7):919–956.
   Google Scholar
• Verghese NR, Barrenetxea J, Bhargava Y, et al. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. J Mark Access Health Policy. 2019 Apr 11;7(1):1601060.
   PubMedGoogle Scholar
• Leopold C, Mantel-Teeuwisse AK, Seyfang L, et al. Impact of external price referencing on medicine prices- A price comparison among 14 European countries. South Med Rev. 2012 Dec;5(2):34–41.
   PubMedGoogle Scholar
• Kalo Z, Alabbadi I, Al Ahdab OG, et al. Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):993–998. .
   PubMed Web of Science ®Google Scholar
• Kalo Z, Voko Z, Akhras KS, et al. Response to: comment on the implications of external price referencing of pharmaceuticals in Middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):15–16. .
   PubMed Web of Science ®Google Scholar
• Gronde TV, Uyl-de Groot CA, Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: a systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017 Aug 16;12(8):e0182613.
   PubMed Web of Science ®Google Scholar
• Malinowski KP, Kawalec P, Trabka W, et al. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. Orphanet J Rare Dis. 2020 Oct 8;15(1):277. 020-01556-9.
   PubMed Web of Science ®Google Scholar
• Ministry of food and drug safety: regulation on designation of orphan drugs. [internet]. cheongju; c2019. [cited 2020 Dec 27]. Available from: https://www.mfds.go.kr/eng/brd/m_18/view.do?seq=71453.
   Google Scholar
• Ministry of food and drug safety: drugs subject to production/import/supply interruption report. [internet]. cheongju; c2020. [cited 2020 Dec 27]. Available from: https://nedrug.mfds.go.kr/pbp/CCBAD01
   Google Scholar
• Ministry of food and drug safety: announcement of orphan drug designation. [internet]. cheongju; c2020. [cited 2020 Dec 27]. Available from: https://www.mfds.go.kr/brd/m_76/list.do
   Google Scholar
• Ministry of food and drug safety: announcement of orphan drug designation.[internet]. cheongju; c2020. [cited 2020 Dec 27]. Available from: https://www.mfds.go.kr/brd/m_76/view.do?seq=14828&srchFr=&srchTo=&srchWord=%ED%9D%AC%EA%B7%80%EC%9D%98%EC%95%BD%ED%92%88&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999&page=1
   Google Scholar
• Ministry of health and welfare: rare disease management act. cheongju; c2019. [cited 2020 Dec 27]. Available from: https://www.law.go.kr/LSW/eng/engLsSc.do?menuId=2&section=lawNm&query=rare&x=30&y=34#liBgcolor1
   Google Scholar
• Ministry of health and welfare: regulation on co-payment benefit for patients with specific diseases. [internet]. cheongju; c2020. [cited 2020 Dec 27]. Available from: https://www.law.go.kr/admRulSc.do?menuId=5&subMenuId=41&tabMenuId=183#liBgcolor2
   Google Scholar
• Korea disease control and prevention agency: diseases subject to medical expenses support project for rare disease patients. [internet]. cheongju; c2020. [cited 2020 Dec 27]. Available from: https://helpline.nih.go.kr/cdchelp/ph/infNoti/selectAnnFrmDetail.do?menu=G0100&pageIndex=&schNtbdCcd=01&ntbdSno=693&schGubun=tit&schText=
   Google Scholar
• RHealth insurance review and assessment service: national drug formulary. [internet]. wonju; c2020. [cited 2020 Dec 27]. Available from: http://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA030014050000
   Google Scholar
• Ministry of health and welfare: criteria for decision or adjustment on drugs. [internet]. wonju; c2020. [cited 2021 Jan 7]. Available from: https://www.law.go.kr/admRulSc.do?menuId=5&subMenuId=41&tabMenuId=183#liBgcolor11
   Google Scholar
• National health insurance service: guidelines for negotiation on drug prices. [internet]. wonju; c2019. [cited 2021 Jan 7]. Available from: https://www.nhis.or.kr/nhis/together/wbhaea02200m01.do?mode=view&articleNo=10802866
   Google Scholar
• McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? BMJ. 2005 Oct 29;331(7523):1016–1019.
   PubMedGoogle Scholar
• McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol. 2010;686:211–222.
   PubMed Web of Science ®Google Scholar
• Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729–737.
   PubMed Web of Science ®Google Scholar
• Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020 Sep; 181: 31. 020-00223-x. eCollection 2020
   PubMed Web of Science ®Google Scholar
• Messori A. Orphan drug pricing: an original exponential model relating price to the number of patients. Sci Pharm. 2016 Jan 24;84(4):618–624.
   PubMed Web of Science ®Google Scholar
• Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the orphan drug system: break or bend? is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012 Sep;7(1):74. 1172-7-74.
   PubMed Web of Science ®Google Scholar
• Schey C, Krabbe PF, Postma MJ, et al. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet J Rare Dis. 2017 Jan 17;12(1). 10,016-0555-3. 10.1186/s13023-016-0555-3
   PubMedGoogle Scholar
• Schey C, Postma MJ, Krabbe PFM, et al. Assessing the preferences for criteria in multi-criteria decision analysis in treatments for rare diseases. Front Public Health. 2020 May;8(8):162. .
   PubMedGoogle Scholar
• Lasalvia P, Prieto-Pinto L, Moreno M, et al. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review. Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):409–420. .
   PubMed Web of Science ®Google Scholar
• Baran-Kooiker A, Czech M, Kooiker C. Multi-criteria decision analysis (MCDA) models in health technology assessment of orphan drugs-a systematic literature review Next steps in methodology development? . Front Public Health. 2018 Oct;6(6):287.
   PubMedGoogle Scholar
• Medic G, Korchagina D, Young KE, et al. Do payers value rarity? an analysis of the relationship between disease rarity and orphan drug prices in Europe. J Mark Access Health Policy. 2017 Apr 10;5(1):1299665.
   PubMedGoogle Scholar
• Lee SH, Yoo SL, Bang JS, et al. Patient accessibility and budget impact of orphan drugs in South Korea: long-term and real-world data analysis (2007-2019). Int J Environ Res Public Health. 2020 Apr 26;17:9. .
   Web of Science ®Google Scholar